Search Results (139)

Androgenetic alopecia (AGA) is associated with follicular miniaturization, oxidative stress, and microinflammation. Hydroxytyrosol (HT) has antioxidant and anti-inflammatory activities, but its mechanisms in AGA remain unclear. Differentially expressed genes (DEGs) from GSE212301 were intersected with predicted HT targets to identify candidate targets. Enrichment analysis, PPI-based hub gene screening, molecular docking, and molecular dynamics (MD) simulations were performed. A total of 506 DEGs and 24 HT-related AGA candidate targets were identified. These targets were enriched in inflammation- and oxidative stress-related pathways, including MAPK, NF-κB, TNF, and HIF-1 signaling. HMOX1, PTGS2, FOS, and JUN were identified as hub genes. Docking showed favorable binding between HT and these targets, particularly PTGS2. The 50 ns MD simulation supported the relative stability of the HT–PTGS2 complex. HT may modulate AGA-related inflammatory and oxidative stress networks, particularly through HMOX1 and PTGS2, providing a basis for further experimental validation. Full article

Background/Objectives: SARS-CoV-2 infection and COVID-19 vaccination have both been linked to post-acute alopecia, yet prevalence, patterns, and correlates remain poorly defined. We aimed to determine the prevalence and patterns of alopecia after SARS-CoV-2 infection and COVID-19 vaccination, and to identify independent correlates among Saudi adults. Methods: A cross-sectional study of 1261 Saudi adults (≥18 years) was conducted nationwide between March and July 2025 using a structured, self-administered, bilingual (Arabic/English) online questionnaire distributed via social media. Eligible participants had received at least one COVID-19 vaccine dose. Data captured demographics, vaccination type and dose history, prior SARS-CoV-2 infection, self-reported alopecia subtype guided by plain-language definitions, comorbidities, and nutritional status. Hair loss and subtypes were entirely self-reported and not clinically or dermoscopically confirmed. Chi-square tests assessed univariate associations, and multivariable logistic regression identified independent predictors of any self-reported hair loss. Results: Mean age was 28.0 ± 9.6 years; 62.1% were female, 97.7% vaccinated (76.0% Pfizer-BioNTech first dose, 58.1% three doses), and 53.6% reported prior COVID-19 infection. Overall self-reported hair loss prevalence was 62.4%, with hair loss reported by 57.5% of vaccinated and 49.7% of COVID-positive participants. Self-reported telogen effluvium was the predominant pattern (56.3%), followed by androgenetic alopecia (39.3%) and alopecia areata (2.7%). Independent correlates were female sex (aOR 4.89; 95% CI 3.78–6.32), vitamin/mineral deficiency (aOR 2.31; 1.73–3.09), iron deficiency anemia (aOR 1.89; 1.29–2.78), prior SARS-CoV-2 infection (aOR 1.31; 1.02–1.68), and COVID-19 vaccination (aOR 7.45; 2.51–22.12). Conclusions: Self-reported hair loss was reported by nearly two-thirds of Saudi adults after COVID-19 vaccination or infection. Female sex and correctable nutritional deficiencies are the strongest modifiable correlates and warrant targeted screening and counseling. Full article

Hair loss, particularly androgenetic alopecia (AGA) and alopecia areata (AA), is a prevalent condition with widespread psychosocial impact. Recently, low-level laser therapy (LLLT) has emerged as a promising non-invasive therapeutic alternative due to its bioregulatory effects and favorable safety profile compared to conventional pharmacological treatments. In this study, we employed fluorescence lifetime imaging microscopy (FLIM) to investigate the effects of red-light irradiation on hair follicle dynamics and the cutaneous microenvironment in a C57BL/6 mouse model. A hair regeneration model was established to evaluate the efficacy of 650 nm red-light irradiation (bandwidth ± 20 nm). Then, the skin tissue was stained with hematoxylin and eosin (H&E) and followed by FLIM analysis to provide a multidimensional assessment of tissue morphology and metabolic status. Results showed that red-light irradiation significantly increased hair follicle numbers and enhanced adenosine triphosphate (ATP) levels in the skin tissue. FLIM analysis further revealed prolonged fluorescence lifetime values across different epidermal and dermal layers in the irradiated group, indicating significant alterations in the skin metabolic microenvironment. Furthermore, phasor plot analysis enabled precise differentiation between hair follicles and their surrounding skin structures, highlighting FLIM’s high sensitivity and accuracy in evaluating hair growth. In conclusion, this study has provided novel imaging-based insights into the mechanisms of LLLT-induced hair regeneration, highlighting the potential of FLIM as a powerful tool for characterizing the cutaneous microenvironment and quantitatively evaluating phototherapeutic efficacy in future translational applications. Full article

Conventional treatments for androgenetic alopecia (AGA) are often limited by suboptimal efficacy and potential adverse effects, highlighting the need for alternative approaches. We aimed to evaluate the efficacy and safety of a multi-targeted cosmetic formulation containing TrinogeniX™, composed of synthetic small-molecule inhibitors of glycogen phosphorylase, the prostaglandin D₂ receptor, and 15-hydroxyprostaglandin dehydrogenase, developed using the artificial intelligence-driven platform DeepZema^®, in individuals with AGA. This 24-week, randomized, double-blind, placebo-controlled trial involved 56 participants, of whom 49 completed the study. Efficacy was assessed using phototrichogram analysis, visual evaluation by dermatologists, and subjective questionnaires. Safety was evaluated based on adverse event reports and dermatological examinations. The test group demonstrated a significant increase in hair density and thickness over 24 weeks (p < 0.05), whereas no significant changes were observed in the placebo group. Expert visual assessments confirmed greater improvements in the test group. Subjective evaluations revealed consistently greater perceived improvements in hair loss symptoms, hair richness, and front hairline conditions in the test group. No adverse events or clinically significant abnormalities were observed. The multi-targeted cosmetic formulation (Motifull hair tonic) significantly improved hair density, thickness, and overall hair condition without adverse effects, suggesting its potential as a safe and effective option for AGA. Clinical trial registration: CRIS No. KCT0010804: A double-blind, randomized, placebo-controlled clinical trial evaluating the efficacy and safety of “Motifull Hair Tonic” (tentative name) for the alleviation of hair loss symptoms. Full article

Androgenetic alopecia (AGA) is a highly prevalent and progressive disorder characterized by follicular miniaturization and dysregulation of the hair follicle microenvironment. Although minoxidil (MXD) and finasteride remain first-line therapies, their long-term efficacy is limited by poor follicular bioavailability, systemic side effects, and suboptimal patient compliance. In recent years, nanotechnology-based strategies have emerged as promising alternatives by enabling efficient follicular targeting and controlled therapeutic delivery. This review critically summarizes recent advances in nanotechnology-enabled approaches for AGA management, including nanocarrier-based formulations and nanotechnology-based microneedle systems. Beyond functioning as passive drug carriers, emerging nanoplatforms increasingly act as active modulators of the follicular niche by attenuating oxidative stress, inflammation, impaired angiogenesis, and stem cell dysfunction—key pathological drivers of AGA progression—thereby representing a conceptual shift from delivery-centered to microenvironment-remodeling strategies. To enhance translational relevance, we compare nanotechnology-based therapies with conventional treatments in terms of efficacy, safety, and clinical feasibility, and summarize representative preclinical studies, patent landscapes, and ongoing or completed clinical trials. Finally, key challenges related to safety evaluation, manufacturing reproducibility, and regulatory classification are discussed, highlighting nanotechnology as a promising framework for next-generation, mechanism-oriented AGA therapy and precision trichology. Full article

Androgenetic alopecia (AGA) and telogen effluvium (TE) are common hair loss disorders characterized by dysregulated hair follicle cycling and impaired dermal papilla cell function. Emerging evidence indicates that exosomes are key mediators of intercellular communication, largely through their microRNA (miRNA) cargo. Milk-derived exosomes (Mi-Exos) represent an accessible and biologically active source of regulatory miRNAs with potential relevance for hair disorders. This study evaluated the in vitro effects of bovine milk-derived exosomes (MEV-miRNAs) on human hair follicles. MEV-miRNAs were enriched in miRNA families (Let-7, miR-21, miR-30, miR-200, and miR-148/152) previously implicated in hair follicle regulation. Viability/metabolic activity of hair follicle dermal papilla (HFDP) cells was assessed, and human hair follicles were cultured ex vivo to measure shaft elongation and modulation of the WNT signaling pathway by qRT-PCR. MEV-miRNAs significantly increased HFDP cell viability after 24 h compared with controls. Human hair follicles showed a non-significant trend toward increased elongation following treatment. Gene expression analysis revealed significant up-regulation of key WNT pathway components, including WNT2, WNT5B, WNT10A, WNT11, MMP7, WISP1, and NKD1, indicating modulation of WNT-associated pathways implicated in hair follicle growth and cycling. Overall, MEV-miRNAs exhibit positive modulatory effects on signaling pathways, supporting their potential as a novel therapeutic strategy for AGA and TE. Full article

Androgenetic alopecia (AGA) is the most common cause of progressive hair thinning in adults and has traditionally been viewed as an androgen-driven inherited condition. Genomic research now demonstrates that AGA is a complex polygenic disorder involving multiple biological pathways, including androgen signaling, hair follicle development, cell survival, and extracellular matrix remodeling. Genome-wide association studies have identified numerous susceptibility loci, revealing that follicle miniaturization arises from interacting molecular mechanisms rather than a single pathogenic process. Genetic risk and predictive value vary across populations, with many loci identified in European cohorts showing limited transferability to other ancestries, highlighting the need for more diverse genetic studies. In women, genetic studies remain underpowered, and emerging data suggest partially distinct risk architecture compared with male AGA. Pharmacogenetic findings indicate that genetic variation may influence response to commonly used therapies, although no markers are currently validated for routine clinical use. Advances in single-cell and multi-omic approaches are improving understanding of how genetic risk translates into follicular dysfunction, supporting the development of more personalized and mechanism-based treatment strategies. Full article

Hair loss disorders, particularly androgenetic alopecia (AGA), are common conditions that carry significant psychosocial impact. Current standard therapies, including minoxidil, finasteride, and hair transplantation, primarily slow progression or re-distribute existing follicles and do not regenerate lost follicular structures. In recent years, regenerative medicine has been associated with a gradual shift toward approaches that aim to restore follicular function and architecture. Stem cell-derived conditioned media and exosomes have shown the ability to activate Wnt/β-catenin signaling, enhance angiogenesis, modulate inflammation, and promote dermal papilla cell survival, resulting in improved hair density and shaft thickness with favorable safety profiles. Autologous cell-based therapies, including adipose-derived stem cells and dermal sheath cup cells, have demonstrated the potential to rescue miniaturized follicles, although durability and standardization remain challenges. Adjunctive interventions such as microneedling and platelet-rich plasma (PRP) further augment follicular regeneration by inducing controlled micro-injury and releasing growth and neurotrophic factors. In parallel, machine learning-based diagnostic tools and deep hair phenotyping offer improved severity scoring, treatment monitoring, and personalized therapeutic planning, while robotic Follicular Unit Excision (FUE) platforms enhance surgical precision and graft preservation. Advances in tissue engineering and 3D follicle organoid culture suggest progress toward producing transplantable follicle units, though large-scale clinical translation is still in early development. Collectively, these emerging biological and technological strategies indicate movement beyond symptomatic management toward more targeted, multimodal approaches. Future progress will depend on standardized protocols, regulatory clarity, and long-term clinical trials to define which regenerative approaches can reliably achieve sustainable follicle renewal in routine cosmetic dermatology practice. Full article

Background and Aims: Androgenetic alopecia (AGA) represents the most prevalent multifactorial condition leading to hair loss, necessitating an enhanced molecular understanding. The aim of this study is to present the analysis integrating protein, mRNA and miRNA between frontal and occipital regions of patients with androgenetic alopecia (AGA) and to identify potential mechanism. Methods and Results: Paired frontal and occipital scalps from four male donors with AGA were collected for transcriptomic and proteomics analyses. The molecular and protein characteristics of AGA were demonstrated by a comprehensive bioinformatics approach. Additionally, immunofluorescence (IF) and dual-luciferase reporter (DLR) assays were employed to confirm the analytical findings. A total of 758 differentially expressed proteins (DEPs), 1802 differentially expressed mRNAs (DERs) and 61 differentially expressed miRNAs (DEmiRNAs) were identified. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses revealed significant enrichments in lipid metabolism, especially those involving PPAR signaling. Co-expression analyses further supported the association of up-regulated genes with lipid metabolism. A protein–protein interaction network analysis, supplemented by KEGG enrichment and the MCE algorithm, pinpointed four candidate genes: DBI, ACAA1, IDH1 and PEX3. IF confirmed significant upregulation of ACAA1 and PEX3 in scalp tissues with AGA, while IDH1 was downregulated and DBI without significant changes. A competing endogenous RNA network indicated that hsa-miR-1343-3p targets ACAA1 and hsa-miR-3609_R-2 targets IDH1, which were confirmed by DLR assays. Conclusions: This study provides preliminary evidence that hsa-miR-1343-3p-mediated regulation of ACAA1 contributes to AGA pathogenesis, suggesting a link between AGA and lipid metabolism. Full article

Androgenetic alopecia (AGA) is closely associated with oxidative stress and vascular dysfunction, which disrupt nutrient delivery to hair follicles and promote follicle miniaturization. Dihydrotestosterone (DHT) exposure impairs human dermal microvascular endothelial cell (HDMEC) function by inducing mitochondrial disruption, excessive reactive oxygen species (ROS) accumulation, and reduced angiogenic capacity. This study evaluated the protective effects of dihydroisoquinolinone piperidinylcarboxy pyrazolopyridine (DPP), a novel 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitor identified through the AI-based discovery platform DeepZema^®, in DHT-exposed HDMECs. DPP markedly reduced intracellular and mitochondrial ROS levels, restored mitochondrial membrane potential, and increased ATP production, thereby alleviating oxidative stress and supporting mitochondrial function. DPP also enhanced endothelial cell migration and capillary-like tube formation, demonstrating the restoration of angiogenic capacity that is essential for sustaining perifollicular vascularization. Moreover, DPP mitigated stress-associated signaling by reducing the phosphorylation of ERK, JNK, and p38 within the MAPK pathway, thereby suggesting the reestablishment of endothelial homeostasis under DHT-induced stress. Collectively, these findings indicate that DPP preserves endothelial function under DHT-driven oxidative conditions. We suggest that DPP may exert complementary protective effects on both vascular and follicular compartments, supporting its potential relevance in hair follicle regeneration. Full article

Background: Regenerative therapies have emerged in recent years. In particular, their utility in managing androgenetic alopecia—the most prevalent hair loss condition worldwide, affecting up to half of adults—is an active area of research. Navigating this space can be challenging for physicians due to widespread commercialization, lack of high-quality evidence, and an evolving regulatory landscape. Objective: To critically review recently published evidence (2020–2025) on platelet-rich plasma, photobiomodulation, stem cells, and exosomes for the treatment of androgenetic alopecia. Methods: A scoping review was conducted using PubMed, Embase (Ovid) and the Cochrane Controlled Register of Trials in February and November of 2025. Combination therapies were excluded. Results and Conclusions: Platelet-rich plasma is the most studied modality, with emerging investigations into newer formulations such as leukocyte-rich and pure platelet-rich plasma. However, recent studies are limited by inconsistent reporting of cellular composition, short follow-up durations, and a lack of comparative data on treatment protocols. The efficacy of photobiomodulation as a monotherapy remains debated, with inconsistent reporting of device parameters. Stem cells and exosomes show promising, though still limited, clinical evidence in inducing hair regrowth. Standardization of these therapies is crucial, with emphasis on transparency, reproducibility, and patient safety. Full article

Alopecia is a multifactorial disorder in which immune, endocrine, metabolic, and microbial systems converge within the follicular microenvironment. In alopecia areata (AA), loss of immune privilege, together with interferon-γ- and interleukin-15-driven activation of the JAK/STAT cascade, promotes cytotoxic infiltration, whereas selective inhibitors, including baricitinib, ritlecitinib, and durvalumab, restore immune balance and permit anagen reentry. In androgenetic alopecia (AGA), excess dihydrotestosterone and androgen receptor signaling increase DKK1 and prostaglandin D2, suppress Wnt and β-catenin activity, and drive follicular miniaturization. Combination approaches utilizing low-dose oral minoxidil, platelet-rich plasma, exosome formulations, and low-level light therapy enhance vascularization, improve mitochondrial function, and reactivate metabolism, collectively supporting sustained regrowth. Elucidation of intracellular axes such as JAK/STAT, Wnt/BMP, AMPK/mTOR, and mitochondrial redox regulation provides a mechanistic basis for rational, multimodal intervention. Advances in stem cell organoids, biomaterial scaffolds, and exosome-based therapeutics extend treatment from suppression toward structural follicle reconstruction. Recognition of microbiome and mitochondria crosstalk underscores the need to maintain microbial homeostasis and redox stability for durable regeneration. This review synthesizes molecular and preclinical advances in AA and AGA, outlining intersecting signaling networks and regenerative interfaces that define a framework for precision and sustained follicular regeneration. Full article

Androgenetic alopecia (AGA) is a prevalent, multifactorial hair disorder affecting a substantial portion of both males and females, with significant psychosocial consequences. Over the past decade, regenerative medicine has reshaped AGA treatment, offering biologically driven alternatives to conventional pharmacological and surgical therapies. Among these, Autologous Micrografting Technology (AMT) (Regenera Activa^® by Rigenera^® Technology, Barcelona, Spain) emerged 10 years ago as a notable innovation leveraging the body’s intrinsic regenerative potential through micrografts derived from a healthy scalp tissue. This review provides a comprehensive overview of the pathophysiology of AGA—including genetic, hormonal, and inflammatory contributors—and evaluates the clinical efficacy, safety, and mechanistic basis of AMT in comparison with other regenerative strategies such as platelet-rich plasma, adipose-derived mesenchymal stem cells, and exosome-based treatments. Clinical studies demonstrate that AMT yields significant short-term improvements in hair density and thickness with favorable safety outcomes. Moreover, advancements in device technology and treatment protocols have enhanced consistency and reproducibility. As multimodal and personalized approaches gain traction in hair restoration, AMT is a minimally invasive point-of-care procedure within the evolving regenerative landscape. Future studies are warranted to optimize treatment algorithms, extend follow-up data, better define patient selection criteria for maximizing outcomes with AMT, and expand the indication of autologous micrografting technology. Full article

Topical tretinoin (all-trans-retinoic acid) is a first-generation vitamin A derivative with well-established efficacy in acne vulgaris and photoaging. Owing to its pleiotropic effects on epidermal differentiation, collagen synthesis, and skin pigmentation, numerous off-label uses have been proposed across dermatology. This narrative review summarizes current evidence on the efficacy and safety of topical tretinoin for multiple dermatological conditions, based on studies published between January 2000 and July 2025. Robust data from randomized clinical trials (RCTs) and systematic reviews support its benefit in acne and photoaging, whereas smaller RCTs and prospective studies indicate potential efficacy for melasma, postinflammatory hyperpigmentation, striae distensae, flat warts, alopecia areata, androgenetic alopecia, hypertrophic scars and keloids, and actinic keratosis and as pretreatment before chemical peels or laser resurfacing. However, high-quality, adequately powered trials with standardized outcome measures are still needed to establish clinical guidelines. Regarding cutaneous oncology, a large RCT demonstrated no preventive effect of tretinoin on keratinocyte carcinomas. Adverse events are typically mild, localized, and transient, and available evidence does not support an association with systemic adverse effects. Full article

Background: Androgenetic alopecia, also known as male pattern baldness (MPB), is a common hair loss disorder among middle-aged men. MPB shares similar risk factors with prostate cancer (PrCa), including advancing age, family history, and sex hormones. Several studies have examined the associations between MPB and PrCa; however, the evidence remains unclear. We carried out an updated meta-analysis of epidemiological studies that examined the relationship between age at onset and patterns of MPB (either frontal, vertex, or both) and their associations with risks of total and aggressive PrCa. Methods: A literature search was performed using PubMed and Web of Science databases for epidemiological studies published between 1 January 2000 and 31 December 2024 that examined the associations between MPB and PrCa. From each eligible study, relevant data were extracted on study design and population, sample size, prevalence of MPB at various ages, and their association with PrCa. Pooled relative risks (RR) and corresponding 95% confidence intervals (CI) were calculated using the Der-Simonian and Laird random-effects models. Heterogeneity across studies was assessed by I² statistics, while the quality of studies was evaluated using the Newcastle–Ottawa Scale. Results: A total of 19 observational studies, including 17,810 cases and 146,806 controls/non-cases, were analyzed. The prevalence of MPB increased from 5% to 65% with aging and varied across the studies. Both frontal and vertex MPB were associated with a pooled RR of 1.08 (95% CI 1.02–1.14) for total PrCa, but there was no association with frontal-only MPB. Younger-onset MPB (<40 years old) was also associated with an RR = 1.13 (95% CI 0.96–1.31) for PrCa, although results were not statistically significant. Vertex-only MPB was associated with more aggressive PrCa (pooled RR = 1.14; 95% CI 1.02–1.25); however, there was substantial heterogeneity in the definition of aggressive PrCa across the studies. Conclusions: Men with both frontal and vertex MPB have a modestly elevated risk of PrCa. However, most studies were conducted in Caucasian men and they did not evaluate effect modifications by genetic variations in androgen metabolism pathway genes or changes in serum levels of androgens with aging. Large prospective cohort studies with more accurate longitudinal assessment of hair loss patterns are needed to better understand the complex relationship between genetic susceptibility, endogenous hormones, MPB, and subsequent risk of PrCa. Full article